Who should not take Follistatin 344?
Documented caution flags for Follistatin 344 include anyone risk-averse to limited human data and pregnancy / nursing. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Follistatin 344 is limited.
Documented caution flags for Follistatin 344
- Anyone risk-averse to limited human data
- Pregnancy / nursing
- Active malignancy
Reported side effects to weigh
- Limited human safety data
- Theoretical: cardiac and tendon issues with chronic strong myostatin suppression
- Injection-site irritation
References
- Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors — Haidet AM, Rizo L, Handy C, et al. (incl. Mendell JR, Kaspar BK), PNAS, 2008
- Follistatin gene delivery enhances muscle growth and strength in nonhuman primates — Kota J, Handy C, Haidet AM, et al. (incl. Kaspar BK), Science Translational Medicine, 2009
- A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy — Mendell JR, et al., Molecular Therapy, 2015 (NCT01519349)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Follistatin 344
Last updated 2026-06-15.